Antiplamodial effect of sulfadoxine/pyrimethamine/clindamycin: A study in parasitized mice

Triple antimalarial combination therapies may overcome the emergence of drug resistance. Sulfadoxine/pyrimethamine (S/P) is an drug. Clindamycin (C) has potential antiplasmodial effect. This study assessed whether activity S/P can be augmented by C on Plasmodium berghei-infected mice. Adult Swiss albino mice (25-30g) were grouped and infected with berghei. The orally treated daily (21.4/10.7 mg/kg), (10mg/kg) S/P/C, respectively using curative, prophylactic suppressive tests. normal negative controls saline (0.2mL) while positive control was chloroquine (CQ) (10mg/kg). After treatment, blood samples collected evaluated for percentage parasitamia hematological parameters. Mice observed mean survival time. In tests, S/P/C significantly decreased levels when compared to SP or at p< 0.05. prolonged time difference S/P, C, produced 65.62 %, 62. 03 % 85.31 inhibitions, CQ 83.72 inhibition. caused significant reduction in anemia marked increased packed cell volume, hemoglobin, red cells white 0.05 C. eradicates liver merozoites central vein congestion. therefore S/PC used malaria treatment.